Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00263003 |
Study Objectives :
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Irbesartan/hydrochlorothiazide Drug: Irbesartan |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Open Label Comparative Study of Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension |
Estimated Enrollment: | 40 |
Study Start Date: | June 2005 |
Ages Eligible for Study: | 20 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
history of significant cardiovascular diseases which includes:
history of significant renal diseases including:
hepatic disease as indicated by any of the following:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study ID Numbers: | PM_L_0094 |
Study First Received: | December 6, 2005 |
Last Updated: | December 6, 2007 |
ClinicalTrials.gov Identifier: | NCT00263003 |
Health Authority: | Taiwan: Department of Health |
Irbesartan Vascular Diseases Angiotensin II Hydrochlorothiazide Hypertension |
Angiotensin II Type 1 Receptor Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Natriuretic Agents Therapeutic Uses Sodium Chloride Symporter Inhibitors |
Physiological Effects of Drugs Diuretics Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |